Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $764 | $830 | $818 | $649 |
| % Growth | -7.9% | 1.4% | 26.1% | – |
| Cost of Goods Sold | $296 | $346 | $305 | $269 |
| Gross Profit | $468 | $483 | $512 | $380 |
| % Margin | 61.2% | 58.3% | 62.7% | 58.6% |
| R&D Expenses | $26 | $25 | $24 | $28 |
| G&A Expenses | $137 | $125 | $110 | $91 |
| SG&A Expenses | $158 | $147 | $130 | $103 |
| Sales & Mktg Exp. | $22 | $22 | $20 | $13 |
| Other Operating Expenses | $104 | $91 | $102 | $67 |
| Operating Expenses | $288 | $263 | $257 | $198 |
| Operating Income | $180 | $220 | $256 | $181 |
| % Margin | 23.5% | 26.6% | 31.3% | 28% |
| Other Income/Exp. Net | -$2 | $0 | $2 | $1 |
| Pre-Tax Income | $178 | $220 | $258 | $183 |
| Tax Expense | $41 | $50 | $58 | $30 |
| Net Income | $137 | $170 | $200 | $153 |
| % Margin | 17.9% | 20.5% | 24.4% | 23.6% |
| EPS | 2.67 | 3.2 | 3.73 | 2.76 |
| % Growth | -16.6% | -14.2% | 35.1% | – |
| EPS Diluted | 2.67 | 3.2 | 3.73 | 2.76 |
| Weighted Avg Shares Out | 51 | 53 | 53 | 55 |
| Weighted Avg Shares Out Dil | 51 | 53 | 53 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $1 |
| Depreciation & Amortization | $21 | $19 | $18 | $16 |
| EBITDA | $200 | $238 | $271 | $197 |
| % Margin | 26.1% | 28.7% | 33.2% | 30.3% |